Mark Hahn - Aug 7, 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Andrew Fisher, Attorney-in-Fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Aug 7, 2024
Transactions value $
-$824,776
Form type
4
Date filed
8/9/2024, 07:11 PM
Previous filing
Aug 5, 2024
Next filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $0 +800K +5.39% $0.00 15.7M Aug 7, 2024 Direct F1, F2
transaction VRNA Ordinary Shares Tax liability -$825K -315K -2.01% $2.62 15.3M Aug 7, 2024 Direct F1, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine.
F3 Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above.
F4 The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8).
F5 Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,514,688 Ordinary Shares underlying 1,564,336 ADSs.